L 250 Pill - yellow capsule/oblong
Pill with imprint L 250 is Yellow, Capsule/Oblong and has been identified as Levetiracetam 250 mg. It is supplied by Karalex Pharma, LLC.
Levetiracetam is used in the treatment of Seizures; Epilepsy and belongs to the drug class pyrrolidine anticonvulsants. Risk cannot be ruled out during pregnancy. Levetiracetam 250 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for L 250
Levetiracetam
- Imprint
- L 250
- Strength
- 250 mg
- Color
- Yellow
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Pyrrolidine anticonvulsants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Karalex Pharma, LLC
- National Drug Code (NDC)
- 42043-0190 (Discontinued)
- Inactive Ingredients
-
silicon dioxide,
corn starch,
croscarmellose sodium,
magnesium stearate,
povidone,
hypromellose 2910 (3 mPa.s),
hypromellose 2910 (6 mPa.s),
titanium dioxide,
polyethylene glycol 4000,
ferric oxide yellow,
FD&C Blue No. 2
Note: Inactive ingredients may vary.
Related images for "L 250"
More about levetiracetam
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (430)
- Drug images
- Latest FDA alerts (6)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: pyrrolidine anticonvulsants
- Breastfeeding
- En español
Patient resources
- Levetiracetam oral/injection drug information
- Levetiracetam Extended-Release Tablets
- Levetiracetam Injection
- Levetiracetam Tablets
- Levetiracetam Oral Solution
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Professional resources
- Levetiracetam monograph
- Levetiracetam (FDA)
- Levetiracetam Extended Release Tablets (FDA)
- Levetiracetam Injection (FDA)
- Levetiracetam Injection, Concentrate (FDA)
- Levetiracetam Solution (FDA)
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.